Mystic Pharmaceuticals(TM) CEO Presents at OneMedPlace Finance Forum
Timothy Sullivan, President and CEO of Austin Texas-based Mystic Pharmaceuticals will present at OneMedPlace Emerging Healthcare Technologies Finance Forum on Jan 7th and 8th in San Francisco at the Sir Francis Drake Hotel in Union Square. A growing company specializing in novel drug delivery technology and pharmaceutical products, Mystic Pharmaceuticals has been selected to be showcased at the forum for its innovative approach and groundbreaking technologies.
The forum was designed to provide a platform for micro cap public companies and early stage venture backed companies to showcase promising health and medical technologies. Approximately 50 companies, both public and private, will present at the conference and many of these will be showing breakthrough technologies.
Sullivan will present the latest developments with Mystic’s VersiDoser™ Drug Delivery Platform. He will also discuss the company’s pilot production facility in Austin, Texas facility and announce new research and development collaborations for the application of Mystic’s VersiDoser technology for pandemic and bioterror vaccine delivery.
The Mystic presentation takes place Monday January 7th at 11:10am in the Windsor Room of the Sir Francis Drake Hotel in San Francisco. Sullivan will also present on Tuesday January 8th at 11:00am as a panel member in a session hosted by the Greater Austin Chamber of Commerce, one of the event sponsors.
San Francisco was chosen for the OneMedPlace Forum to coincide with the JP Morgan Healthcare Conference, also held in the first week of January. Now in its 26th year, the JP Morgan Conference has become an important annual event in the sector, attracting nearly 10,000 healthcare executives and financiers.
About Mystic Pharmaceuticals, Inc.
Mystic Pharmaceuticals™ is an integrated specialty pharmaceutical company based in Austin, Texas. Mystic develops precision unit dose drug delivery technology platforms for pharmaceuticals, biologic agents, vaccines and other compounds for ophthalmic and intranasal applications. Mystic combines its novel drug delivery systems with a pipeline of pharmaceuticals and biologics under development by Mystic or its partners, to meet the expanding global market demand for pharmaceutical products which are lower cost, simplified in administration and provide enhanced compliance for consumers.
For more information please visit the Mystic website: www.mysticpharmaceuticals.com.